NLS Pharmaceutics reports preclinical results from in vitro studies targeting α-synuclein for Parkinson’s disease
June 28, 2024
NLS Pharmaceutics Ltd. has announced preclinical results from in vitro studies targeting α-synuclein, specifically the A53T mutation, demonstrating the potential of Aexon Labs Inc.’s compounds for Parkinson’s disease.